Form 4: Xeris Biopharma CFO Reports Equity Changes

Xeris Biopharma's CFO, Steven Pieper, reported significant changes in his beneficial ownership, including new RSU grants and stock option acquisitions, alongside tax-related share disposals.

Summary

• Steven Pieper, Chief Financial Officer of Xeris Biopharma Holdings, Inc. (XERS), acquired 154,986 shares of common stock through a restricted stock unit (RSU) grant on January 30, 2026, with a price of $0 per share.
• These RSU shares are set to vest in equal annual installments over three years, contingent on continued employment.
• Pieper also acquired 207,207 stock options on January 30, 2026, with an exercise price of $7.36 per share, which will vest in equal annual installments over three years, subject to continued service, and expire on January 30, 2036.
• On January 31, 2026, Pieper disposed of a total of 205,534 shares of common stock (111,765, 66,450, and 27,319 shares) at a price of $7.36 per share.
• These disposals were made to satisfy income tax and withholding obligations related to the net settlement of vested restricted stock units.
• Following these transactions, Pieper beneficially owns 1,367,013 shares of common stock and 207,207 stock options.
• All transactions were made pursuant to the Company's 2018 Stock Option and Incentive Plan and were pre-arranged under a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. While there are tax-related share disposals, the significant grants of new RSUs and stock options to the CFO demonstrate continued executive alignment and commitment to the company's long-term success.

Positives

• The acquisition of 154,986 restricted stock units and 207,207 stock options aligns the CFO's interests with those of shareholders, demonstrating continued commitment to the company's long-term performance.
• The vesting schedule over three years for both RSUs and stock options encourages long-term retention and performance from a key executive.

Negatives

• The disposal of 205,534 shares of common stock, while for tax withholding purposes, reduces the CFO's direct shareholding.

Risks

• The vesting of RSUs and stock options is subject to the CFO's continued employment or service, meaning the full benefit is not guaranteed if employment ceases prematurely.
• The value of the stock options and vested shares is subject to market fluctuations of Xeris Biopharma's common stock.

Future Outlook

The acquired restricted stock units and stock options are subject to a three-year vesting schedule, indicating a future commitment to the company's performance and the CFO's continued service.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and stock options is a standard practice in executive compensation across the biopharmaceutical industry. These equity awards are designed to align the interests of executives with those of shareholders by tying a significant portion of their compensation to the company's stock performance and long-term value creation. The tax-related sales are also a routine part of RSU vesting for executives.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with multi-year vesting, is consistent with common practices observed in comparable biopharma companies such as BioMarin Pharmaceutical Inc. (BMRN) or Acadia Pharmaceuticals Inc. (ACAD), which utilize similar long-term incentive plans to retain key talent and incentivize performance.
• The exercise price of $7.36 for the stock options aligns with the market price at the time of the tax-related disposals, suggesting a fair market value grant, typical for executive options.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's financial interests with shareholder value creation over the long term.
• Employees: The compensation structure reflects the company's incentive plans, potentially influencing broader employee compensation strategies.

Next Steps

• The acquired restricted stock units and stock options will vest in equal annual installments over the next three years, subject to continued employment/service.

Key Dates

Recommendation

This Form 4 filing primarily details routine executive compensation and tax-related transactions. While the acquisition of new equity by the CFO is a positive indicator of management alignment, it does not present new fundamental information that would warrant a change in investment thesis. The tax-related sales are standard and not indicative of a lack of confidence. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Xeris Biopharma, XERS, Form 4, Insider Transaction, Steven Pieper, CFO, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Beneficial Ownership, Rule 10b5-1